Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Instituto De Salud Carlos Iii is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. The prosecution involves a distinct examiner, suggesting a narrow and specific range of current patent office interactions. This action constitutes the entirety of the pending workload for the organization, which may reflect a selective filing strategy for their medical research outputs.
The examination process is localized in 1 distinct art unit. BRIAN J GANGLE is the busiest examiner for this portfolio, currently overseeing a pending office action. Because the total number of pending actions is limited, this examiner is responsible for all of the company's current prosecution tasks. This indicates a centralized review process for their pharmaceutical and biotechnological innovations, where the examiner's specific interpretation of the prior art will be the primary factor in the progress of the application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702767 | LIPOPOLYSACCHARIDE (LPS) DEFICIENT ACINETOBACTER BAUMANNII MULTIVALENT VACCINE | GANGLE, BRIAN J | 56d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702767 | LIPOPOLYSACCHARIDE (LPS) DEFICIENT ACINETOBACTER BAUMANNII MULTIVALENT VACCINE | GANGLE, BRIAN J | 1645 | §112 | Non-Final OA | 56d | Pending | Apr 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial